The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Metrics other than potency reveal systematic variation in responses to cancer drugs
Open accessAbstract
Large-scale analysis of cellular response to anti-cancer drugs typically focuses on variation in potency (IC50) assuming that it is the most important difference between effective/ineffective drugs or sensitive/resistant cells. We took a multi-parametric approach involving analysis of the slope of the dose-response curve (HS), the area under the curve (AUC) and the maximum effect (Emax). We found that some of these parameters vary systematically with cell line and others with drug class. For cell-cycle inhibitors, Emax often but not always correlated with cell proliferation rate. For drugs targeting the Akt/PI3K/mTOR pathway dose-response curves were unusually shallow. Classical pharmacology has no ready explanation for this phenomenon but single-cell analysis showed that it correlated with significant and heritable cell-to-cell variability in the extent of target inhibition. We conclude that parameters other than potency should be considered in the comparative analysis of drug response, particularly at clinically relevant concentrations near and above IC50.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Elements of Information Theory
Cover, T. M., & Thomas, J. A. (2001) · Wiley eBooks · doi:10.1002/0471200611 · Cited by 36,808
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
Goodall, C. (1988) · Technometrics · doi:10.1080/00401706.1988.10488412 · Cited by 8,675
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
The NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Cyclin is degraded by the ubiquitin pathway
Glotzer, M., Murray, A. W., & Kirschner, M. W. (1991) · Nature · doi:10.1038/349132a0 · Cited by 2,357
The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves
Hill, A. V., Hill, A. L., & Hill, A. V. (1910) · The Journal of Physiology · Cited by 2,181
Cited by
A community effort to assess and improve drug sensitivity prediction algorithms
Community, N. D., Costello, J. C., Heiser, L. M., Georgii, E., Gönen, M., Menden, M. P., Wang, N. J., Bansal, M., Ammad-ud-din, M., Hintsanen, P., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2877 · Cited by 772
Self-citationGrowth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
Hafner, M., Niepel, M., Chung, M., & Sorger, P. K. (2016) · Nature Methods · doi:10.1038/nmeth.3853 · Cited by 681
Self-citationDiverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
Ramirez, M., Rajaram, S., Steininger, R. J., Osipchuk, D., Roth, M. A., Morinishi, L. S., Evans, L., Ji, W., Hsu, C.-H., Thurley, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms10690 · Cited by 581
Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method
Lin, J.-R., Fallahi-Sichani, M., & Sorger, P. K. (2015) · Nature Communications · doi:10.1038/ncomms9390 · Cited by 562
Self-citationYadav, B., Pemovska, T., Szwajda, A., Kulesskiy, E., Kontro, M., Karjalainen, R., Majumder, M. M., Malani, D., Murumägi, A., Knowles, J., et al. (2014) · Scientific Reports · doi:10.1038/srep05193 · Cited by 359
Schütte, M., Risch, T., Abdavi-Azar, N., Boehnke, K., Schumacher, D., Keil, M., Yildiriman, R., Jandrasits, C., Borodina, T., Amstislavskiy, V., et al. (2017) · Nature Communications · doi:10.1038/ncomms14262 · Cited by 339
Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
Wensink, G. E., Elias, S. G., Mullenders, J., Koopman, M., Boj, S. F., Kranenburg, O. W., & Roodhart, J. M. L. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00168-1 · Cited by 323
Independent Drug Action in Combination Therapy: Implications for Precision Oncology
Plana, D., Palmer, A. C., & Sorger, P. K. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0212 · Cited by 307
Self-citationDouble PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
Vasan, N., Razavi, P., Johnson, J. L., Shao, H., Shah, H., Antoine, A., Ladewig, E., Gorelick, A., Lin, T.-Y., Toska, E., et al. (2019) · Science · doi:10.1126/science.aaw9032 · Cited by 283
Quantifying drug combination synergy along potency and efficacy axes
Meyer, C. T., Wooten, D. J., Paudel, B. B., Bauer, J., Hardeman, K. N., Westover, D., Lovly, C. M., Harris, L. A., Tyson, D. R., & Quaranta, V. (2019) · Cell Systems · doi:10.1016/j.cels.2019.01.003 · Cited by 202
In Vitro Human Cell Line Models to Predict Clinical Response to Anticancer Drugs
Niu, N., & Wang, L. (2015) · Pharmacogenomics · doi:10.2217/pgs.14.170 · Cited by 162
PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies
Smirnov, P., Kofia, V., Maru, A., Freeman, M., Ho, C., El-Hachem, N., Adam, G.-A., Ba-alawi, W., Safikhani, Z., & Haibe-Kains, B. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx911 · Cited by 155
Surviving apoptosis: life–death signaling in single cells
Flusberg, D. A., & Sorger, P. K. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.03.003 · Cited by 149
Self-citationFröhlich, F., Kessler, T., Weindl, D., Shadrin, A., Schmiester, L., Hache, H., Muradyan, A., Schütte, M., Lim, J.-H., Heinig, M., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.10.013 · Cited by 143
“, 2016), evaluation methods (Fallahi-Sichani et al., 2013; Pozdeyev et al., 2016), as well as shortcomings in the employed assay protocols (Hafner et al.”
MethodComparison of Drug Inhibitory Effects ($$\hbox {IC}_{50}$$) in Monolayer and Spheroid Cultures
Berrouet, C., Dorilas, N., Rejniak, K. A., & Tuncer, N. (2020) · Bulletin of Mathematical Biology · doi:10.1007/s11538-020-00746-7 · Cited by 133
GRcalculator: an online tool for calculating and mining dose–response data
Clark, N. A., Hafner, M., Kouril, M., Williams, E. H., Muhlich, J. L., Pilarczyk, M., Niepel, M., Sorger, P. K., & Medvedovic, M. (2017) · BMC Cancer · doi:10.1186/s12885-017-3689-3 · Cited by 121
Self-citationFallahi‐Sichani, M., Moerke, N. J., Niepel, M., Zhang, T., Gray, N. S., & Sorger, P. K. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145877 · Cited by 99
“Variation in Emax and in the slope of the dose– response curve can play a significant role in limiting the efficacy of anti-cancer drugs (Fallahi-Sichani et al, 2013).”
Self-citationWooten, D. J., Meyer, C. T., Lubbock, A. L. R., Quaranta, V., & Lopez, C. F. (2021) · Nature Communications · doi:10.1038/s41467-021-24789-z · Cited by 97
An unbiased metric of antiproliferative drug effect in vitro
Harris, L. A., Frick, P. L., Garbett, S. P., Hardeman, K. N., Paudel, B. B., Lopez, C. F., Quaranta, V., & Tyson, D. R. (2016) · Nature Methods · doi:10.1038/nmeth.3852 · Cited by 92
Multilevel models Improve precision and Speed of IC 50 Estimates
Vis, D. J., Bombardelli, L., Lightfoot, H., Iorio, F., Garnett, M. J., & Wessels, L. F. (2016) · Pharmacogenomics · doi:10.2217/pgs.16.15 · Cited by 71
Hall, S. R., Rasmussen, S. A., Crittenden, E., Dawson, C. A., Bartlett, K. E., Westhorpe, A. P., Albulescu, L.-O., Kool, J., Gutiérrez, J. M., & Casewell, N. R. (2023) · Nature Communications · doi:10.1038/s41467-023-43510-w · Cited by 63
Multidimensional profiling in the investigation of small-molecule-induced cell death
Wolpaw, A. J., & Stockwell, B. R. (2014) · Methods in Enzymology · doi:10.1016/b978-0-12-801430-1.00011-1 · Cited by 10
Ho, K. K. Y., Srivastava, S., Kinnunen, P. C., Garikipati, K., Luker, G. D., & Luker, K. E. (2023) · Bioengineering · doi:10.3390/bioengineering10020269 · Cited by 8
Human iPSC Models in Drug Discovery: Opportunities and Challenges
Silva, M. C., Cross, A., Brandon, N. J., & Haggarty, S. J. (2017) · Comprehensive Medicinal Chemistry III · doi:10.1016/b978-0-12-409547-2.12284-x · Cited by 6
Metadata
- Authors
- Fallahi-Sichani, M., Honarnejad, S., Heiser, L. M., Gray, J. W., & Sorger, P. K.
- Venue
- Nature Chemical Biology
- Published
- 2013-09-08
- Volume
- 9
- Issue
- 11
- Pages
- 708-714
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W2078448804
- Cited by
- 314
- References
- 37
- FWCI
- 26.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.